We have studied the pharmokinetics of cis-trans, trans-trans and cis-cis mivacurium in 10 healthy subjects and 11 patients with mild or moderate hepatic cirrhosis, during nitrous oxide-oxygenisoflurane anaesthesia. Mivacurium 15ugkg-1 min" 1 was infused for 10min (total dose 0.15 mg kg-1 ) and the plasma concentration of the three isomers measured at regular intervals for 190 min. The electromyographic response to the drug was also measured. Compartmental analysis of the resulting isomer profiles was undertaken: one-and two-compartment models were fitted to derive clearance, volume of distribution and half-life. Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg" 1 min" 1 vs 95 (57-213) ml kg" 1 min-1 (P<0.05); trans-trans 32 (12-64) ml kg" 1 min" 1 vs 70 (34-101) ml kg" 1 min" 1 (P<0.05). The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg" 1 min" 1 ) compared with the healthy group (5.2 (2.9-8.9) ml kg" 1 min" 1 ) was not significant with this sample size. Clearance of each isomer correlated significantly with plasma cholinesterase activity: cis-trans r = 0.73, P < 0.001; trans-trans r = 0.69, P < 0.001; cis-cis r = 0.48, P < 0.05. Terminal half-life was prolonged significantly for the cis-trans and transtrans isomers in the cirrhotic patients compared with the healthy subjects: cis-trans 2.5 (1.3-64.6) min vs 1.5 (0.7-2.2) min (P<0.05); trans-trans 11.1 (2.8-36.9) min vs 2.3 (1.2-7.8) min {P < 0.001), but was not statistically significant for the cis-cis isomer: 60.8 (8.7-155) min vs 50.3 (12.6-237) min. Volume of distribution was similar for all three isomers in the healthy and cirrhotic groups. Onset and recovery from neuromuscular block were slower in the cirrhotic compared with the healthy group: time to 90% depression of T1/T0 6.8 (5.8-11.5) min vs 5.9 (5.3-10.3) min (P<0.05); recovery index (25-75% recovery of T1/T0) 11.8 (5.6-26.3) min vs 7.4 (4.7-9.6) min (A 3 < 0.01). There was a significant negative correlation between all recovery variables and plasma cholinesterase activity. (Br. J. Anaesth. 1994; 73: 613-618) 
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Summary
We have studied the pharmokinetics of cis-trans, trans-trans and cis-cis mivacurium in 10 healthy subjects and 11 patients with mild or moderate hepatic cirrhosis, during nitrous oxide-oxygenisoflurane anaesthesia. Mivacurium 15ugkg-1 min"
1 was infused for 10min (total dose 0.15 mg kg- 1 ) and the plasma concentration of the three isomers measured at regular intervals for 190 min. The electromyographic response to the drug was also measured. Compartmental analysis of the resulting isomer profiles was undertaken: one-and two-compartment models were fitted to derive clearance, volume of distribution and half-life. Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg" 1 min" 1 vs 95 (57-213) ml kg" (P<0.05). The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg" 1 min" 1 ) compared with the healthy group (5.2 (2.9-8.9) ml kg" 1 min" 1 ) was not significant with this sample size. Clearance of each isomer correlated significantly with plasma cholinesterase activity: cis-trans r = 0.73, P < 0.001; trans-trans r = 0.69, P < 0.001; cis-cis r = 0.48, P < 0.05. Terminal half-life was prolonged significantly for the cis-trans and transtrans isomers in the cirrhotic patients compared with the healthy subjects: cis-trans 2.5 (1.3-64.6) min vs 1.5 (0.7-2.2) min (P<0.05); trans-trans 11.1 (2.8-36.9) min vs 2.3 (1.2-7.8) min {P < 0.001), but was not statistically significant for the cis-cis isomer: 60.8 (8.7-155) min vs 50.3 (12.6-237) min. Volume of distribution was similar for all three isomers in the healthy and cirrhotic groups. Onset and recovery from neuromuscular block were slower in the cirrhotic compared with the healthy group: time to 90% depression of T1/T0 6.8 (5.8-11.5) A solution of mivacurium chloride contains three non-interchangeable stereoisomers, trans-trans (57 %), cis-trans (37 %) and cis-cis (6 %), which are thought to be metabolized by plasma cholinesterase [1] . The aim of this study was to compare the pharmacokinetics of each isomer in healthy subjects and in patients with hepatic cirrhosis, a condition known to cause a reduction in plasma cholinesterase activity [2] .
Previous pharmacokinetic studies of mivacurium in hepatic cirrhosis failed to analyse the three isomers separately [3] . Thus Cook and colleagues found the terminal elimination half-life to be an order of magnitude greater than that expected from the duration of action of the drug. This difficulty was resolved by the advent of a stereospecific assay, which suggested that the long terminal half-life they reported was entirely the result of the largely inactive cis-cis isomer, which has less than 10% of the activity of the two other isomers in cats [4] . Cook and colleagues calculated the combined clearance of the two shorter acting "active" isomers to be 70.4 ml kg" 1 min~' in healthy subjects and 33.3 ml kg" 1 min" 1 in patients with liver failure [3] .
In healthy subjects, preliminary data using a stereospecific assay also suggested a high clearance for cis-trans (138 ml kg" 1 min" 1 ) and trans-trans (70 ml kg" 1 min" 1 ) mivacurium. The clearance of ciscis mivacurium (5.7 ml kg-1 min-1 ) was similar to that of other non-depolarizing neuromuscular blocking drugs [5] .
We have therefore studied the pharmacokinetics of the three isomers of mivacurium in healthy subjects and in those with hepatic cirrhosis using a stereospecific assay.
Patients and methods
The study was approved by the Committee of Safety of Medicines and the Hospital Ethics Committee. All patients gave written, informed consent. We studied 11 patients with hepatic cirrhosis and 10 healthy subjects (ASA grades I and II). All cirrhotic patients were undergoing injection sclero therapy of oesophageal varices. The healthy subjects were Patients were excluded if they had a history of neuromuscular disorder, asthma, renal failure, difficult tracheal intubation or if they were receiving drugs known to interfere with neuromuscular transmission, plasma cholinesterase activity, hepatic function or the HPLC assay. All patients with cirrhosis were receiving ranitidine 150 mg orally twice daily and vitamin K 10 mg daily. Child's B and C patients were also receiving spironolactone 100-^400 mg orally daily.
Before operation, all patients had measurements of haemoglobin concentration, platelet count, urea, electrolytes and plasma albumin concentrations; liver function tests were also performed. Before surgery, plasma cholinesterase activity was measured using a spectrophotometric method [7] and the dibucaine and fluoride numbers were determined [8] . Prothrombin and activated partial thromboplastin times were measured in the cirrhotic patients. ASA II and III patients had a chest x-ray and electrocardiogram before operation.
Premedication comprised oral diazepam 10 mg, except in the Child's group C cirrhotic patient, in whom no premedication was given. Anaesthesia was induced with fentanyl 1 ug kg" 1 and thiopentone 3-5 mg kg" 1 , followed by a period of at least 15 min during which the patient breathed isofiurane and 70 % nitrous oxide in oxygen, until a stable end-tidal isoflurane concentration of 0.5 % (Capnomac, Datex) had been achieved. End-tidal carbon dioxide partial pressure was maintained at 4.5-5.5 kPa; ventilation was assisted when necessary.
During this period, electromyographic monitoring was begun, applying train-of-four (TOF) stimuli to the ulnar nerve at the wrist at 12-s intervals and recording the surface compound action potential over the adductor pollicis using a Medelec MS6 [9] . An i.v. cannula was inserted in one limb for infusion of mivacurium and a separate 14-gauge cannula was placed for blood sampling in the arm used to monitor the electromyographic response. This arm was wrapped in cotton wool padding, but skin temperature was not measured.
When the end-tidal isoflurane concentration was stable, and after obtaining a baseline blood sample, mivacurium was infused using an Ohmeda 9000 pump at a rate of 15 ug kg" 1 min" 1 for 10 min (total dose 0.15 mg kg" 1 ). Blood samples (7 ml) were obtained at 1, 2, 4, 6, 8, 10, 11, 12, 14, 16, 19, 22, 25, 30, 40, 70 , 100, 130 and 190 min after starting the infusion of mivacurium and placed immediately into lithium-heparin bottles containing phospholine iodide 5 mg to inhibit plasma cholinesterase. After separation, plasma samples were frozen until analysis.
Electromyographic monitoring was continued throughout surgery and until the first response (T1/T0) had recovered to at least 85% of control and the TOF ratio (T4/T1) had reached at least 80%. Neither supplementary doses of mivacurium nor an anticholinesterase was used. Increments of fentanyl and thiopentone were given when indicated clinically. After completion of surgery, and when T4/T1 was greater than 80%, anaesthesia was discontinued and, when ventilation was considered adequate, the trachea was extubated.
The isomeric content of any batch of mivacurium may vary slightly. All drug used in this study was supplied by the Wellcome Foundation pic. It was known to have a total mivacurium content of 105.01 % of that stated on the label, and the relative proportions of the three isomers were: cis-trans 36.16%, trans-trans 57.84% and cis-cis 6.0%.
Mivacurium isomer concentrations were determined using a stereospecific HPLC assay. The drug assay was automated (ASPEC, Gilson). The isomers of mivacurium were extracted from plasma by a solid phase technique (Phenyl Bond-Elut cartridges), separated chromatographically on a strong cation exchange (Spherisorb SCX5) column and detected fluorimetrically. The lower limit of detection of the assay was 2.5 ng ml" 1 , calibration was linear over the range 2.5-480 ng ml" 1 and the coefficient of variation was less than 20%.
Compartmental analysis of the resulting isomer profiles were carried out using the NONMEM program in single patient mode [10] ; one-and twocompartment models were fitted. A two-compartment model was preferred if it resulted in a significant decrease in the NONMEM objective function (more than 7.6, P < 0.05). Values for clearance and total (steady state) volume of distribution were obtained from the compartmental analysis and the terminal half-life was calculated using standard formulae [11] . Elimination was assumed to be from the central compartment only.
The electromyographic recording from each patient was analysed to determine times to 90%, 95% and maximum depression of T1/T0, and the maximum depression of T1/T0 (%) achieved. Times to recovery of T1/T0 to 10%, 25%, 50% and 75 %, recovery index (time for T1/T0 to recover from 25 % to 75 %) and the time for T4/T1 to return to 70 % were also noted.
Comparison of physical characteristics and cholinesterase activity of the two groups was performed using Student's unpaired r-test. Comparison of the pharmacokinetic variables of the two groups was made using the Mann-Whitney U test, and correlation of plasma clearance and cholinesterase activity with Pearson's correlation coefficient. Onset and recovery data for the cirrhotic and healthy groups were compared using the Mann-Whitney U test.
Results
Patient characteristics and plasma cholinesterase activity are shown in table 2. There was a preponderance of males among the cirrhotic patients. Only one patient had severe hepatic cirrhosis (Child's group C), five were Child's group A patients and five Child's group B. Liver function tests for the healthy and cirrhotic patients are shown in table 3.
Cholinesterase activity was significantly reduced in the cirrhotic group (table 2) . Only four cirrhotic patients had cholinesterase activity within the normal range (table 3) . Dibucaine numbers were normal in all subjects, but three of the healthy subjects were fluoride-resistant heterozygotes (fluoride numbers 39, 48, 54; normal range 55-67) with normal cholinesterase activity.
Mean plasma concentrations for the cis-trans, trans-trans and cis-cis isomers during and after the 10-min infusion in the two groups are shown in figure 1 . Plasma concentrations of the three isomers were higher in the cirrhotic patients and were detectable for a longer period. A two-compartment model was a significantly better fit than that of a onecompartment model in 19 of the 21 data sets for the cis-cis isomer, in 11 of the 21 data sets for the transtrans isomer and in 4 of the 20 data sets for the cistrans isomer. In general, two-compartment models provided a significant improvement in fit for those data sets where drug was detectable for a prolonged period after cessation of the infusion.
Values for clearance, terminal half-life and volume of distribution for each isomer are shown in table 4. Clearance was reduced significantly and the terminal half-life prolonged significantly for the cis-trans and trans-trans isomers in the cirrhotic patients. The difference in these variables between the two groups was not statistically significant for the cis-cis isomer with this sample size. There was no significant difference in the volume of distribution of any isomer between the healthy and cirrhotic patients.
Clearance of each isomer correlated significantly with cholinesterase activity (fig. 2 ). This correlation was greater for the two short-acting isomers, cistrans (r = 0.73, P < 0.001) and trans-trans (r = 0.69, P < 0.001) than for the cis-cis isomer (r = 0.48, P < 0.05) ( fig. 2) . Table 4 Median (range) clearance (C/), terminal half-life (Tf) and volume of distribution (V) for the three isomers of mivacurium in the healthy subjects (n = 10 for the cts-trans isomer, n = 9 for the trans-trans and cis-cis isomers) and in the cirrhotic patients (n = 11)
Cis-trans
Cl (ml kg" 1 min" Onset of block was prolonged in the cirrhotic group, although this only reached statistical significance for 90 % depression of T1/T0 (table 5) . There was no correlation between onset times and plasma cholinesterase activity.
Recovery from block was also prolonged in the cirrhotic group, but this only reached statistical significance for 75 % T1/T0, the recovery index and for 70% T4:T1 (table 6 ). There was a significant negative correlation between all recovery variables and plasma cholinesterase activity (10%, r = -0.49, P<0.05; 25%, r = -0.63, P<0.01; 50%, r = -0.68, P< 0.001; 75%, r = -0.69, P< 0.001; T4/T1 70%, r = -0.67, P < 0.001; recovery index, r = -0.66, P< 0.001).
Discussion
A large number of anaesthetic drugs are chiral mixtures [12] . To define the pharmacokinetics of chiral mixtures of a drug presents some difficulty, particularly when different forms have dramatically ) for the healthy subjects (open symbols) and the cirrhotic patients (closed symbols).This correlation was greater for the two short-acting isomers, cis-trans (r = 0.73, P < 0.001) and trans-trans (r = 0.69, P < 0.001) than for the cis-cis isomer (r = 0.48, P < 0.05). different properties. Without a stereospecific assay, determination of the plasma concentrations and pharmacokinetics of such mixtures may be extremely misleading, and according to one author, may be little better than "sophisticated nonsense" [13] .
Early pharmacokinetic work on mivacurium highlighted this problem: Cook and colleagues found the elimination half-life of mivacurium (measured as a single entity) to be greatly in excess of that which might be expected from its short duration of action (18.4 min in healthy subjects, 34.3 min in patients with liver failure). A later stereospecific assay showed this terminal phase to be the result of the largely inactive cis-cis isomer [3] . Therefore, Cook and colleagues extrapolated the log-linear terminal portion of the plasma elimination curve back to time zero, and subtracted this from the total mivacurium concentration (the sum of the three isomers), to obtain an estimate for the concentrations of the sum of the two "active" isomers, cis-trans and trans-trans mivacurium. In addition to being highly derived, this required the further assumption that the cis-cis isomer should have a one-compartment distribution, which is questionable [14] .
The cis-cis isomer, which constitutes only about 6 % of the solution of mivacurium, has been demonstrated to have less than 10% of the potency of the cis-trans and trans-trans isomers in the cat [4] . Stereospecific studies have since shown that the pharmacokinetics of the cis-cis isomer differ markedly from the two other isomers [5, [15] [16] [17] and trans-trans 70 and 58 ml kg" 1 min" 1 have been reported [5, 16] . This different behaviour has been confirmed in vitro, where the cis-cis isomer has been shown to be metabolized by plasma cholinesterase, but at a much slower rate than that reported for the cis-trans and trans-trans isomers [18, 19] .
This study denned stereospecifically the pharmacokinetics of the three isomers of mivacurium in healthy subjects and in those with cirrhosis of the liver. Clearance values for the cis-trans and transtrans isomers were high, a finding consistent with previous pharmacokinetic studies [3, 19] . The clearance of the cis-cis isomer was similar to that of other non-depolarizing neuromuscular blocking agents such as atracurium [20] . The volumes of distribution of the three isomers did not differ between healthy and cirrhotic patients; this contrasts with other nondepolarizing neuromuscular blocking agents (with the possible exception of vecuronium [20] ) where the volume of distribution was increased in cirrhosis [21] [22] [23] .
Elimination of the two more active isomers from plasma is very rapid and this creates difficulties with data analysis. The cis-trans isomer is the most rapidly cleared from plasma and a one-compartment model is preferred in the majority of cases; this may be because of a relative paucity of sampling points (this isomer was undetectable 8 min after the end of infusion in many patients). In those patients in whom clearance of the trans-trans isomer was high, similar considerations may apply. A two-compartment model was preferred in the majority of patients for the cis-cis isomer, which has a relatively low clearance and in which sufficient sampling points were available to allow definition of a biphasic decline in plasma concentration. Arterial sampling may be more informative as it facilitates increased frequency of sampling. Using a larger total dose of mivacurium may also yield more data points: the infusion procedure used in this study produced low plasma concentrations of the more rapidly cleared isomers.
The main finding of the present study was the reduced clearance and prolonged elimination halflife of the two active isomers, cis-trans and transtrans, in patients with hepatic cirrhosis. Median values for clearance were halved for these two isomers in the cirrhotic group {cis-trans from 95 to 44 ml kg" 1 min" 1 and trans-trans from 70 to 32 ml kg" 1 min" 1 ). This reduction in clearance correlates significantly with cholinesterase activity, suggesting a pharmacokinetic basis for the prolonged action of mivacurium in patients with hepatic cirrhosis [3, 24] .
Interesting, although clearance of die cis-cis isomer was reduced and the elimination half-life prolonged in cirrhotic patients, these changes were not statistically significant: this may have been because of the small sample size, and a difference may indeed exist. Population analysis might help to explain some of this dichotomy; it has been used previously to approach the pharmacokinetics of cis-cis mivacurium, and has suggested multiple routes of elimination [17] . It may be that this isomer is eliminated by several pathways, of which cholinesterase metabolism represents but one (perhaps minor) component. Thus changes in plasma cholinesterase activity would be expected to influence the elimination of the cis-cis isomer much less dramatically than the cis-trans and trans-trans isomers, whose elimination is largely dependent on this enzyme.
